Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1799-1805

  Wang, Guoliang ^a   Sai, K E ^b   Gong, Fanghe ^a   Yang, Qunying ^b   Chen, Furong ^b   Lin, Jian ^a  

^a General Hospital of GuangZhou Military Command of PLA   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cell proliferation; Glioma; Hypoxia inducible factor 1 ; Isocitrate dehydrogenase 1; Nuclear factor B

Indexed keywords

AMINO ACID; ARGININE; HISTIDINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 1; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN E; ENZYME ACTIVATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; I-KAPPA B PROTEINS; ISOCITRATE DEHYDROGENASE; MUTATION; NF-KAPPA B; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MYC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899550794     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2052     Document Type: Article

References (45)

1. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
2. Balss J, Meyer J, Mueller W, et al: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602, 2008.
3. Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153, 2009.
4. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
5. Ichimura K: Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 29: 131-139, 2012.
6. Ramachandran N and Colman RF: Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase. J Biol Chem 255: 8859-8864, 1980.
7. Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347, 2009.
8. Hartmann C, Hentschel B, Wick W, et al: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120: 707-718, 2010.
9. Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324: 261-265, 2009.
10. Dang L, White DW, Gross S, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744, 2009.
11. Sahm F, Capper D, Pusch S, et al: Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol 22: 26-31, 2012.
12. Hughes JM, Groot AJ, van der Groep P, et al: Active HIF-1 in the normal human retina. J Histochem Cytochem 58: 247-254, 2010.
13. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
14. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066, 2009.
15. Taylor CT: Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J Physiol 586: 4055-4059, 2008.
16. Walmsley SR, Farahi N, Peyssonnaux C, et al: Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med 201: 105-115, 2005. (Pubitemid 40130088)
17. Bruning U, Fitzpatrick SF, Frank T, et al: NFkappaB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci 69: 1319-1329, 2012.
18. Koong AC, Chen EY and Giaccia AJ: Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 54: 1425-1430, 1994. (Pubitemid 24106401)
19. Kenneth NS and Rocha S: Regulation of gene expression by hypoxia. Biochem J 414: 19-29, 2008.
20. Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pflugers Arch 450: 363-371, 2005. (Pubitemid 41380694)
21. Laver T, Nozell S and Benveniste EN: The NF-κB signaling pathway in GBMs: implications for apoptotic and inflammatory responses and exploitation for therapy. In: CNS Cancer, Cancer Drug Discovery and Development. Van Meir EG (ed). Springer, pp1011-1036, 2009.
22. Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684, 2006.
23. Perkins ND: The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 25: 434-440, 2000.
24. Perkins ND and Gilmore TD: Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13: 759-772, 2006.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
26. Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29: 19-35, 2007. (Pubitemid 46985299)
27. Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 233: 21-31, 2008.
28. Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082, 2007.
29. Reitman ZJ and Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932-941, 2010.
30. Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-κB in development and progression of human cancer. Virchows Arch 446: 475-482, 2005. (Pubitemid 40884279)
31. Scortegagna M, Cataisson C, Martin RJ, et al: HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 111: 3343-3354, 2008.
32. Cockman ME, Lancaster DE, Stolze IP, et al: Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci USA 103: 14767-14772 2006. (Pubitemid 44527803)
33. Cummins EP, Berra E, Comerford KM, et al: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 103: 18154-18159, 2006. (Pubitemid 44871628)
34. Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81-S96, 2002.
35. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
36. Abdullah JM, Ahmad F, Ahmad KA, et al: Molecular genetic analysis of BAX and cyclin D1 genes in patients with malignant glioma. Neurol Res 29: 239-242, 2007. (Pubitemid 46802358)
37. Arato-Ohshima T and Sawa H: Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer 83: 387-392, 1999. (Pubitemid 29455763)
38. Zhang X, Zhao M, Huang AY, et al: The effect of cyclin D expression on cell proliferation in human gliomas. J Clin Neurosci 12: 166-168, 2005. (Pubitemid 40326663)
39. Liao DJ, Thakur A, Wu J, Biliran H and Sarkar FH: Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog 13: 93-158, 2007. (Pubitemid 350274298)
40. Robson S, Pelengaris S and Khan M: c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Pat Anticancer Drug Discov 1: 305-326, 2006.
41. Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007, 2009.
42. Houillier C, Wang X, Kaloshi G, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566, 2010.
43. SongTao Q, Lei Y, Si G, et al: IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103: 269-273, 2012.
44. Lee SM, Koh HJ, Park DC, et al: Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32: 1185-1196, 2002. (Pubitemid 34603355)
45. Rohle D, Popovici-Muller J, Palaskas N, et al: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340: 626-630, 2013.